Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer


I'm Interested

Trial ID: NCT06080061


The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Official Title

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Stanford Investigator(s)

Lucas Kas Vitzthum, MD
Lucas Kas Vitzthum, MD

Clinical Associate Professor, Radiation Oncology - Radiation Therapy


Inclusion Criteria:

* Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
* ECOG performance status of 0-2
* Age \> 18 years old
* Ability to understand and the willingness to personally sign the written IRB approved informed consent document
* Estimated life expectancy of 12 weeks or longer

Exclusion Criteria:

* Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
* Age \< 18 years old
* Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
* Diagnosis of interstitial pulmonary fibrosis
* Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields


radiation: Hypofractionated accelerated radiation therapy


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jillian Skerchak

New Trial Alerts